To Increase Patient Access

Post Category: Brain Cancer

November 9, 2023
EBCI Attends SNO 2023

The End Brain Cancer Initiative team is proud to be attending the 2023 Society for Neuro-Oncology Annual Meeting (SNO)

Read More
September 18, 2023
FDA Widens Temodar's Approval to Fight Another Brain Cancer Type

The FDA expanded use of Temodar to include two new indications for the treatment of adults with anaplastic astrocytoma.

Read More
January 27, 2023
Sonodynamic Therapy Clinical Trial

Read about this NEW Clinical Trial and review the eligibility guidelines! "The Ivy Brain Tumor Center at Barrow Neurological Institute is conducting a Phase 1/2 study of sonodynamic therapy (SDT) in patients with recurrent glioblastoma (rGBM).

Read More
January 20, 2023
New cell therapy engineered to kill and prevent brain cancer in advanced mouse model

Scientists at Brigham and Women’s Hospital are harnessing a new way to turn cancer cells into potent, anti-cancer agents. Khalid Shah and his team have developed a new cancer-killing vaccine that can be used to treat existing tumors and prevent recurrences.

Read More
November 17, 2022
End Brain Cancer Mobile App Is Here!

To advance our mission of education and advocacy, we have developed a mobile app where you can find information and interact with the Brain Tumor Community. Download the app today.

Read More
October 27, 2022
20 Years of Improving Patient Access!

Meet the Mission Team behind our Programs that deliver our Mission and Advocacy efforts!

Read More
October 13, 2022
Making a Difference in Healthcare

Dellann Elliott Mydland, President & Board Chair, End Brain Cancer Initiative (EBCI), is a dynamic competitor due to her experience taking down brain tumors, brain cancer, and metastasized disease to the brain. Read her new article in The Corporate Magazine.

Read More
February 28, 2022
“Incisionless Surgery” Treatment Approach: Metabolic Targeting of GBM

This month’s CURE MAG Cover Tip brought to you by the End Brain Cancer Initiative,  and through our patient advocacy and disease education partnership with CURE, focuses on Glioblastoma Multiforme (GBM).

Read More
September 10, 2021
The Importance of Shared Decision-Making for Patients With Glioblastoma

Navigating care for patients with cancer can be overwhelming considering the multiple specialists they encounter and the numerous decisions they must make. For patients with GBM management is further complicated by a poor prognosis, feelings of isolation, urgency to treat, and cognitive decline.

Read More
January 19, 2021
Expanded Use of Innovative Brain Tumor Treatment Exemplified in GT Medical Technologies’ 2020 GammaTile® Therapy

Exciting news from Corporate Partner GT Medical who offer a truly groundbreaking treatment for those undergoing surgery for their brain tumor in the form of safe and effective surgically targeted radiation delivered right to the tumor site.

Read More
December 19, 2020
KIYATEC – A potential game-changer in informing your brain tumor treatment decision

Groundbreaking news in the battle against brain cancer.It’s a response-prediction test which improves outcomes by testing live cancer cells against a number of potential therapies to demonstrate which ones will be most effective in killing the tumor cells.

Read More
June 1, 2020
We SEE You! Nominations Open For EBCI's 2020 National "HOPE AWARD"…

One of my most favorite things to do under my leadership of the EndBrainCancer Initiative is to talk directly to patients with brain cancer and to hear first hand, “their story” and to “see” with my own eyes as well as to “hear” with my own ears how they IMPACT others.

Read More
1 2 3


Enhancing patient outcomes by expanding FDA-approved treatment modalities and fueling research in the pharma/bio/life sciences, device & diagnostic industries and by closing the existing GAP from initial diagnosis to IMMEDIATE AND EXPANDED ACCESS to specialists, researchers, advanced & innovative treatments, clinical trials and critical care with the ultimate goal of improving patient outcomes through updating and improving WHO & NCCN Guidelines and clinical practices related to Standard of Care for brain cancer patients.

TAX ID:26-2185614
corporate partners
upcoming events
About us
linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram